ALMS ALUMIS INC.
Healthcare · Pharmaceutical Preparations · Market cap: $715.1M
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $0 | $0 |
| 2022-Q2 | $0 | $0 |
| 2022-Q3 | $0 | $0 |
| 2022-Q4 | $0 | $0 |
| 2023-Q1 | $0 | $0 |
| 2023-Q2 | $0 | $0 |
| 2023-Q3 | $0 | $0 |
| 2023-Q4 | $0 | $0 |
| 2024-Q1 | $0 | $0 |
| 2024-Q2 | $0 | $0 |
| 2024-Q3 | $145.0M | $0 |
| 2024-Q4 | $0 | $0 |
| 2025-Q1 | $0 | $0 |
| 2025-Q2 | $2.3M | $0 |
| 2025-Q3 | $0 | $0 |
| 2025-Q4 | $20.0M | $0 |
| 2026-Q1 | $31.0M | $0 |
| 2026-Q2 | $0 | $0 |
| 2026-Q3 | $8.3M | $1.5M |
| 2026-Q4 | $0 | $23.6K |
Bought$206.5M45 buy days
Sold$1.6M14 sell days
Net insider flow+$205.0Mnet buying · 5 years
Latest trade2026-11-02Schroer John R.
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2026-11-02 | Sell | Schroer John R. | CFO | 794 | $6.52 | $5.2K | 1 |
| 2026-11-02 | Sell | Hardiman Roy C. | Other C-suite | 652 | $6.52 | $4.3K | 1 |
| 2026-11-02 | Sell | Goldstein David M | Other C-suite | 629 | $6.52 | $4.1K | 1 |
| 2026-11-02 | Sell | Bradley Mark Christopher | Other C-suite | 623 | $6.52 | $4.1K | 1 |
| 2026-11-02 | Sell | Drappa Jorn | Other C-suite | 593 | $6.52 | $3.9K | 1 |
| 2026-11-02 | Sell | Pangali Sanam | Other C-suite | 332 | $6.52 | $2.2K | 1 |
| 2026-09-08 | Buy | AKKARAJU SRINIVAS | Director | 546,581 | $10.63 | $5.8M | 2 |
| 2026-09-08 | Sell | AKKARAJU SRINIVAS | Director | 96,131 | $10.55 | $1.0M | 2 |
| 2026-09-04 | Buy | AKKARAJU SRINIVAS | Director | 220,070 | $11.17 | $2.5M | 1 |
| 2026-08-03 | Sell | Schroer John R. | CFO | 3,282 | $26.37 | $86.5K | 1 |
| 2026-08-03 | Sell | Hardiman Roy C. | Other C-suite | 2,692 | $26.37 | $71.0K | 1 |
| 2026-08-03 | Sell | Goldstein David M | Other C-suite | 2,596 | $26.37 | $68.5K | 1 |
| 2026-08-03 | Sell | Bradley Mark Christopher | Other C-suite | 2,572 | $26.37 | $67.8K | 1 |
| 2026-08-03 | Sell | Drappa Jorn | Other C-suite | 2,447 | $26.37 | $64.5K | 1 |
| 2026-08-03 | Sell | Pangali Sanam | Other C-suite | 1,364 | $26.37 | $36.0K | 1 |
| 2026-07-06 | Sell | Pangali Sanam | Other C-suite | 5,000 | $28.00 | $140.0K | 1 |
| 2026-01-09 | Buy | AKKARAJU SRINIVAS | Director | 588,235 | $17.00 | $10.0M | 1 |
| 2026-01-08 | Buy | Foresite Labs, LLC | 10% owner | 411,764 | $17.00 | $7.0M | 2 |
| 2026-01-08 | Buy | Tananbaum James B. | Director | 411,764 | $17.00 | $7.0M | 2 |
| 2026-01-08 | Buy | Foresite Capital Fund V, L.P. | 10% owner | 411,764 | $17.00 | $7.0M | 2 |
| 2025-12-05 | Buy | AKKARAJU SRINIVAS | Director | 186,377 | $9.84 | $1.8M | 3 |
| 2025-12-04 | Buy | AKKARAJU SRINIVAS | Director | 66,027 | $8.18 | $540.1K | 1 |
| 2025-12-03 | Buy | AKKARAJU SRINIVAS | Director | 100,000 | $7.75 | $775.0K | 1 |
| 2025-12-02 | Buy | AKKARAJU SRINIVAS | Director | 96,000 | $7.55 | $724.8K | 1 |
| 2025-12-01 | Buy | AKKARAJU SRINIVAS | Director | 86,350 | $7.46 | $644.2K | 1 |
| 2025-11-28 | Buy | AKKARAJU SRINIVAS | Director | 38,702 | $7.64 | $295.7K | 1 |
| 2025-11-26 | Buy | AKKARAJU SRINIVAS | Director | 48,537 | $7.64 | $370.8K | 1 |
| 2025-11-21 | Buy | Tananbaum James B. | Director | 72,212 | $7.38 | $532.9K | 1 |
| 2025-11-21 | Buy | Foresite Labs, LLC | 10% owner | 72,212 | $7.38 | $532.9K | 1 |
| 2025-11-21 | Buy | Foresite Capital Fund V, L.P. | 10% owner | 72,212 | $7.38 | $532.9K | 1 |
| 2025-11-20 | Buy | AKKARAJU SRINIVAS | Director | 125,743 | $7.20 | $905.3K | 1 |
| 2025-11-19 | Buy | Tananbaum James B. | Director | 190,500 | $6.56 | $1.2M | 1 |
| 2025-11-19 | Buy | Foresite Labs, LLC | 10% owner | 190,500 | $6.56 | $1.2M | 1 |
| 2025-11-19 | Buy | Foresite Capital Fund V, L.P. | 10% owner | 190,500 | $6.56 | $1.2M | 1 |
| 2025-11-19 | Buy | AKKARAJU SRINIVAS | Director | 137,772 | $6.56 | $903.8K | 1 |
| 2025-11-18 | Buy | Foresite Capital Fund V, L.P. | 10% owner | 117,374 | $6.19 | $726.5K | 1 |
| 2025-11-18 | Buy | Foresite Labs, LLC | 10% owner | 117,374 | $6.19 | $726.5K | 1 |
| 2025-11-18 | Buy | Tananbaum James B. | Director | 117,374 | $6.19 | $726.5K | 1 |
| 2025-11-18 | Buy | AKKARAJU SRINIVAS | Director | 102,652 | $6.05 | $621.0K | 1 |
| 2025-11-17 | Buy | Tananbaum James B. | Director | 200,000 | $5.59 | $1.1M | 2 |
| 2025-11-17 | Buy | Foresite Capital Fund V, L.P. | 10% owner | 200,000 | $5.59 | $1.1M | 2 |
| 2025-11-17 | Buy | Foresite Labs, LLC | 10% owner | 200,000 | $5.59 | $1.1M | 2 |
| 2025-11-17 | Buy | AKKARAJU SRINIVAS | Director | 914 | $5.51 | $5.0K | 1 |
| 2025-11-13 | Buy | AKKARAJU SRINIVAS | Director | 276,179 | $5.25 | $1.4M | 1 |
| 2025-05-06 | Buy | Tananbaum James B. | Director | 20,000 | $4.34 | $86.8K | 1 |
| 2025-05-06 | Buy | Foresite Capital Fund V, L.P. | 10% owner | 20,000 | $4.34 | $86.8K | 1 |
| 2025-05-06 | Buy | Foresite Labs, LLC | 10% owner | 20,000 | $4.34 | $86.8K | 1 |
| 2025-05-05 | Buy | AKKARAJU SRINIVAS | Director | 160,370 | $4.67 | $749.7K | 2 |
| 2025-05-02 | Buy | AKKARAJU SRINIVAS | Director | 159,920 | $4.55 | $727.6K | 1 |
| 2025-05-02 | Buy | Foresite Capital Fund V, L.P. | 10% owner | 25,000 | $4.62 | $115.5K | 1 |
| 2025-05-02 | Buy | Tananbaum James B. | Director | 25,000 | $4.62 | $115.5K | 1 |
| 2025-05-02 | Buy | Foresite Labs, LLC | 10% owner | 25,000 | $4.62 | $115.5K | 1 |
| 2025-04-02 | Buy | Colowick Alan | Director | 2,300 | $7.49 | $17.2K | 1 |
| 2025-04-01 | Buy | Colowick Alan | Director | 16,104 | $6.97 | $112.2K | 1 |
| 2025-04-01 | Buy | Babler Martin | CEO | 15,650 | $6.44 | $100.8K | 1 |
| 2024-07-01 | Buy | Tananbaum James B. | Director | 2,500,000 | $16.00 | $40.0M | 2 |
| 2024-07-01 | Buy | Foresite Capital Fund V, L.P. | 10% owner | 2,500,000 | $16.00 | $40.0M | 2 |
| 2024-07-01 | Buy | Foresite Labs, LLC | 10% owner | 2,500,000 | $16.00 | $40.0M | 2 |
| 2024-07-01 | Buy | AKKARAJU SRINIVAS | Director | 1,562,500 | $16.00 | $25.0M | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director | $53.8M | $1.0M | 2026-09-08 |
| Foresite Capital Fund V, L.P. | 10% owner | $50.8M | $0 | 2026-01-08 |
| Foresite Labs, LLC | 10% owner | $50.8M | $0 | 2026-01-08 |
| Tananbaum James B. | Director | $50.8M | $0 | 2026-01-08 |
| Pangali Sanam | Other C-suite | $0 | $178.1K | 2026-11-02 |
| Colowick Alan | Director | $129.5K | $0 | 2025-04-02 |
| Babler Martin | CEO | $100.8K | $0 | 2025-04-01 |
| Schroer John R. | CFO | $0 | $91.7K | 2026-11-02 |
| Hardiman Roy C. | Other C-suite | $0 | $75.2K | 2026-11-02 |
| Goldstein David M | Other C-suite | $0 | $72.6K | 2026-11-02 |
| Bradley Mark Christopher | Other C-suite | $0 | $71.9K | 2026-11-02 |
| Drappa Jorn | Other C-suite | $0 | $68.4K | 2026-11-02 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2026-01-08 → 2026-01-09 | 4 | $31.0M | 47 | +29.6% (+28.5% raw) | +13.0% (+15.9% raw) | +17.5% (+30.6% raw) | closed |
| 2025-11-13 → 2025-12-05 | 4 | $20.0M | 63 | +47.0% (+54.2% raw) | +275.9% (+287.3% raw) | +184.9% (+208.0% raw) | closed |
| 2025-04-01 → 2025-05-06 | 6 | $2.3M | 67 | -30.3% (-23.3% raw) | -18.8% (-7.5% raw) | -26.6% (-2.4% raw) | closed |
| 2024-07-01 | 4 | $145.0M | 48 | +3.2% (-3.0% raw) | -21.2% (-18.0% raw) | -38.9% (-30.9% raw) | closed |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.